Preliminary Report of Nationwide COVID-19 Vaccine Compensation in Taiwan.

Publication date: Jun 24, 2024

The potential adverse effects of coronavirus disease 2019 (COVID-19) vaccinations raise public concerns. Data from Taiwan’s Vaccine Injury Compensation Program (VICP) can provide valuable insights. This study analyzed the preliminary application data for COVID-19 vaccine compensation in Taiwan’s VICP, focusing on applicants receiving vaccines between March 2021 and June 2022. Among the 2941 adverse events, 113 cases (3. 8%) were deemed causally associated with vaccination, 313 (10. 6%) were indeterminate, and 2515 (85. 5%) had no causal association. Nearly half (47. 6%) of the applicants were over 60 years old, and 76. 6% had a history of pre-existing chronic diseases. Among the 426 vaccine-associated or indeterminate cases, the most common causes were hematological diseases and thrombosis. There were 920 mortality cases reported, and 97. 4% were unassociated with vaccination. Only five deaths were judged to be associated with the COVID-19 vaccination, all involving the adenovirus vector vaccine and thrombosis with thrombocytopenia syndrome. In conclusion, most compensation applications were not causally linked to vaccination. Compared to other countries, the number of applications in Taiwan’s VICP is relatively high. These findings may indicate a need to adjust the application requirements for compensation in Taiwan’s program.

Open Access PDF

Concepts	Keywords
Coronavirus	coronavirus disease 2019 vaccine
Healthcare	vaccine adverse events
June
Taiwan
Valuable

Semantics

Type	Source	Name
disease	VO	report
disease	VO	COVID-19 vaccine
disease	MESH	coronavirus disease 2019
disease	VO	vaccine
disease	VO	vaccination
disease	IDO	history
disease	MESH	chronic diseases
disease	MESH	causes
disease	MESH	hematological diseases
disease	MESH	thrombosis
disease	MESH	thrombocytopenia
disease	MESH	syndrome
disease	MESH	Infectious Diseases
disease	VO	coronavirus vaccine
disease	VO	effective
disease	MESH	emergency
disease	MESH	infection
disease	VO	population
disease	VO	USA
disease	VO	efficiency
disease	MESH	complications
drug	DRUGBANK	Coenzyme M
disease	VO	immunization
disease	MESH	cardiovascular diseases
disease	MESH	hypertension
disease	MESH	coronary artery diseases
disease	MESH	cardiac arrhythmia
disease	MESH	metabolic diseases
disease	MESH	diabetes mellitus
disease	MESH	hyperlipidemia
disease	MESH	renal failure
disease	MESH	hydronephrosis
disease	MESH	tumors
disease	MESH	stroke
disease	MESH	cerebral hemorrhage
disease	MESH	epilepsy
disease	MESH	dementia
disease	MESH	Parkinsonism
disease	MESH	psychiatric disorders
disease	MESH	hepatobiliary disorders
disease	MESH	respiratory tract diseases
disease	VO	nose
disease	MESH	orthopedic disorders
disease	MESH	anaphylaxis
disease	VO	adverse event
disease	MESH	heart failure
disease	MESH	myocarditis
disease	MESH	pericarditis
disease	MESH	aortic dissection
disease	MESH	encephalitis
disease	MESH	nervous system disorders
disease	MESH	facial palsy
disease	MESH	hearing loss
disease	MESH	sepsis
disease	MESH	cellulitis
disease	MESH	urticaria
disease	MESH	allergic reactions
disease	MESH	peripheral nervous system disorders
disease	MESH	pneumonia
disease	IDO	symptom

Original Article

(Visited 1 times, 1 visits today)